Shanghai Bao Pharmaceuticals (HKG:2659) submitted filing materials related to the proposed implementation of its Hong Kong-listed share full circulation with the China Securities Regulatory Commission, according to a Tuesday Hong Kong bourse filing.
The biotechnology company is looking to convert over 63.1 million unlisted shares into Hong Kong-listed shares.
The shares represent around 19.36% of the firm's issued share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments